Article & Resources
A new, independent report from the York Health Economics Consortium (YHEC) on prostate cancer biopsies, has validated the improved health outcomes and economic benefits of the PrecisionPointTM transperineal prostate biopsy methodology under local anaesthetic (LA TP).
My dad had prostate cancer when he was 65. Does this make me more likely to get it too? What could increase my risk and how will I know if I have it?
BXTA welcomes European Commercial Leader & Clinical Applications Specialist team members amidst continued international growth.
Nurse-led service transformation: a pathway to professional advancement – and better patient care
A new research paper recently published gives further weight to the eradication of the transrectal (TR) prostate biopsy from the prostate cancer pathway.
New study adds evidence to the important role of MRI & systematic biopsy in prostate cancer diagnosis
Patients treated with Low Dose Rate Brachytherapy boost therapy in combination with External Beam Radiotherapy achieve more effective PSA control
Like Bill Turnbull and Stephen Fry, Russell is keen to make more men aware of the importance of getting themselves checked early and regularly.
David Robb was a 68-year-old retired secondary school teacher from Peebles, Scotland when he was diagnosed with prostate cancer last Summer.
THE SOUTH WEST CANCER ALLIANCE MOVES TOWARDS ERADICATION OF ‘TRUS’ PROSTATE CANCER BIOPSY
BXTACCELYON BECOMES GLOBAL DISTRIBUTION PARTNER FOR NEW ONLINE PROSTATE MRI SELF-LEARNING TOOL, MRI PRO, TO ENHANCE PROSTATE CANCER DIAGNOSIS
State of the Art Stokes Centre for Urology to host Two-day Uro-Oncology Masterclass covering latest Innovations in Prostate Cancer Pathway
All men with suspected prostate cancer should be offered a specialist MRI scan when they’re referred to the hospital in England, before a biopsy.
LDR Brachytherapy – Latest study indicates acceptable GU toxicity in patients with prostate cancer treated with permanent seed implantation (PI)
BXTAccelyon addresses concerns that patients may be misled by news of HDR brachytherapy monotreatment
Prostate cancer in Scotland: an evolutionary journey By Karen Walker, Clinical Nurse Specialist,Edinburgh Cancer Centre
Chris was diagnosed with prostate cancer at the age of 67, having previously been treated for testicular cancer in 1976. His treatment pathway took many turns and below is his story.
Kevin Darragh began his prostate cancer treatment journey back in December 2012. After researching and discussing treatment options with those close to him, Kevin decided on brachytherapy
John Morris’ story is an example of how far prostate cancer diagnosis and treatment, as well as men’s attitudes to the disease, have evolved in the last 10 years. It also proves the validity of low dose rate brachytherapy (LDR-B) as a long-standing, clinically proven treatment option with minimal quality of live side effects compared to other treatments
BXTAccelyon attend the 9th Annual Urology in General Practice (UroGP) Symposium 2018
LDR Brachytherapy: A minimally invasive curative treatment with excellent oncological and functional outcomes
Better Quality of life scores after brachytherapy in comparison to radical prostatectomy
Edinburgh Cancer Centre: supporting open thinking in prostate cancer treatment options
ASCENDE RT study: intermediate and high risk prostate cancer patients have double the survival chance with brachytherapy seeds
Implants boost odds of halting prostate cancer: Men treated with radioactive ‘seeds’ twice as likely to find disease has stabilised after five years
Sorry, there are currently no posts with that category.